- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07948070
A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects With Pancreatic Cancer
Clinical Application Study of Rejuvenated Tumor-Reactive T Cells in Pancreatic Cancer
A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects with Pancreatic Cancer
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Hao Jihui
- Número de telefone: +86-02223340123
- E-mail: haojihui@tjmuch.com
Locais de estudo
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China
- Recrutamento
- Tianjin Medical University Cancer Institute & Hospital
-
Contato:
- Hao Jihui, MD
- Número de telefone: +86-02223340123
- E-mail: haojihui@tjmuch.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Informed Consent Form (ICF) .
- Aged 18 to 70 years (inclusive) at the time of signing the ICF.
- Cytology or pathology confirmed Patients with pancreatic tumors.
Cohort 1:
- The subject has undergone radical total resection of the primary tumor with curative intent, as determined by the investigator.
- Adjuvant chemotherapy completed, as determined by the investigator.
Cohort 2:
- Disease progression after prior standard systemic antitumor therapy for the current disease stage;
- Inability to continue standard therapy due to clinically significant and intolerable toxicities, as determined by the investigator, during prior standard treatment;
- No standard treatment option is currently available, tolerable, and expected to provide clinical benefit for the participant, based on current clinical practice and the investigator's judgment;
- For locally recurrent disease, radical surgical resection is deemed unsuitable by the investigator.
Cohort 3:
-
Patients receiving standard chemotherapy regimens include, but are not limited to:
- the oFOLFIRINOX regimen;
- gemcitabine combined with nab-paclitaxel; or
- other standard first-line or second-line chemotherapy regimens as determined by the investigator according to local clinical practice guidelines.
-
Patients receiving targeted therapy must meet all the following criteria:
- Molecular testing confirms a clearly actionable biomarker abnormality (including, but not limited to, BRCA1/2 mutations, KRAS G12C mutation, HER2 alterations, NTRK fusions, or MSI-H/dMMR status);
- The investigator determines that no contraindications exist for the proposed targeted therapy.
-
ECOG score of 0 ~1 .
-
Expected survival time is more than 12 weeks.
-
Negative blood pregnancy test for females of childbearing potential is required.
Exclusion Criteria:
- Patients with central nervous system (CNS) metastasis, leptomeningeal disease, or metastatic spinal cord compression; or a history of CNS disorders, including but not limited to epilepsy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, etc.
- History of bone marrow or organ transplantation;
- History of other primary malignancies;
- Hepatitis B surface antigen (HBsAg) positivity; With negative HBsAg but positive hepatitis B core antibody (HBcAb) ,and if peripheral blood hepatitis B virus (HBV) DNA positive; Hepatitis C virus (HCV) antibody positive and HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Both Treponema pallidum-specific and non-specific antibody tests are positive.
- Patients with a known allergy to any component of the study drugs.
- History of active tuberculosis infection within 1 year prior to screening (subjects with a history of active tuberculosis infection more than 1 year ago are eligible if, in the investigator's judgment, there is no current evidence of active tuberculosis).
- Concurrent or previous history of interstitial lung disease or interstitial pneumonia; presence of chronic lung disease or other respiratory conditions that significantly impair lung function.
- Diagnosis of active autoimmune disease or a history of autoimmune disease that may recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, psoriasis, etc.), or at risk of such conditions.
- Clinically significant thyroid dysfunction as assessed by the investigator.
- Any uncontrolled active infection requiring parenteral (IV) antibiotic, antiviral, or antifungal treatment at the time of signing the ICF or within 4 weeks before the first infusion.
- Clinically significant cardiovascular diseases.
- Insufficient bone marrow reserve or insufficient organ function.
- Female subjects who are pregnant or breastfeeding.
- Administration of attenuated or inactivated vaccines within 28 days before signing the ICF, or planned administration of such vaccines during the screening period.
- The investigator considers that the subject's complications or other conditions may affect compliance with the protocol or that the subject is unsuitable for participation in this study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Coorte 1
|
Combination with Adjuvant Chemotherapy |
|
Experimental: Coorte 2
|
GKPTZ-01 |
|
Experimental: Coorte 3
|
Combination with Chemotherapy or Targeted Therapy |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Recurrence-Free Survival
Prazo: 2 years
|
6 months RFS(recurrence-free survival) rate(cohort 1) |
2 years
|
|
Objective response rate
Prazo: 2 years
|
Proportion of subjects achieving complete response (CR) and partial response (PR)(cohort 2&3) |
2 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Disease Control Rate(DCR)
Prazo: 2 years
|
Proportion of subjects achieving best response of CR, PR, or SD treated with GKPTZ-01 |
2 years
|
|
Duration of Response(DOR)
Prazo: 2 years
|
Time from first documented evidence of confirmed CR or PR until the first documented evidence of disease progression or death, whichever occurs earlier |
2 years
|
|
Progression-free Survival(PFS)
Prazo: 2 years
|
Time from GKPTZ-01 treatment to disease progression or death |
2 years
|
|
Overall survival(OS)
Prazo: 2 years
|
Time from GKPTZ-01 treatment to death |
2 years
|
|
Adverse events
Prazo: 2 years
|
The incidence and severity of AEs (Adverse Events) and SAEs (Serious Adverse Events). |
2 years
|
|
Patient Quality of Life
Prazo: 2 years
|
EORTC(European Organisation for Research and Treatment of Cancer) QLG (Quality of Life Group)Core Questionnaire (EORTC QLQ-C30) |
2 years
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pharmacokinetic
Prazo: 2 years
|
Levels of T-cell Receptor copies |
2 years
|
|
Biomarker
Prazo: 2 years
|
Concentration levels of serum cytokines, tumor markers |
2 years
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- GATEWAY
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .